Kidney transplant patients get extra COVID shot in new trial

NCT ID NCT05220397

Terminated Disease control Sponsor: Mark Stegall Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested whether a dose of the Janssen COVID-19 vaccine could boost immunity in kidney transplant recipients who had already received two or three mRNA vaccine doses. The study enrolled 468 participants and also looked at reducing immunosuppression medication. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Janssen Ad26.CoV2.S vaccine
What this could lead to: If successful, this could show that an extra dose of a different COVID-19 vaccine helps protect kidney transplant patients who had low immunity from mRNA vaccines.
What could go wrong: The trial was terminated early, so results are limited. It is also a small, single-center study, and the vaccine may not work as well in people on strong immunosuppressants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT RECIPIENT

Contacts and locations

Locations

Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.